Clomiphene Citrate: Comprehensive Research Overview

Document Version: 2.0 Last Updated: January 2026 Classification: Research Paper - Hormone Replacement Therapy (Male HRT)

Goal Relevance:

• Boost testosterone levels naturally without using traditional testosterone replacement therapy
• Improve sperm quality and increase chances of conception for men facing infertility issues
• Maintain fertility while undergoing hormone optimization for low testosterone
• Enhance energy and vitality by addressing symptoms of low testosterone in men
• Support reproductive health and increase the likelihood of successful ovulation in women with ovulatory dysfunction
• Aid in managing symptoms of polycystic ovary syndrome (PCOS) by inducing ovulation

1. Executive Summary + Regulatory Classification

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that was approved by the FDA on February 1, 1967 for the treatment of ovulatory dysfunction in women. Over the past two decades, clomiphene has gained recognition as an off-label treatment for male hypogonadism, particularly in men wishing to preserve fertility.

Primary Mechanisms

Selective Estrogen Receptor Modulation:

• Binds to estrogen receptors in hypothalamus and pituitary
• Blocks negative feedback of estrogen on CNS
• Increases GnRH and gonadotropin (LH, FSH) secretion
• Stimulates endogenous testosterone production

Tissue-Specific Effects:

• Estrogen antagonist at hypothalamus/pituitary (blocks negative feedback)
• Dual agonist/antagonist properties depending on estrogen concentration and receptor subtype
• ERα: Agonist with low estrogen, antagonist with high estrogen
• ERβ: Pure antagonist regardless of estrogen levels

Clinical Applications

FDA-Approved (Female):

1. Anovulatory Infertility - Induces ovulation in women with ovulatory dysfunction
2. Polycystic Ovary Syndrome (PCOS) - First-line ovulation induction therapy

Off-Label (Male - AUA-Recognized):

1. Hypogonadotropic Hypogonadism - Increases testosterone in men with low/normal LH
2. Fertility Preservation - Maintains spermatogenesis during or as alternative to TRT
3. Male Infertility - Improves sperm parameters in oligospermia

Regulatory Status Summary

• FDA Approval: 1967 for female ovulatory dysfunction
• Male Use: Off-label but AUA-supported
• DEA Schedule: Not controlled substance federally
• WADA: Prohibited at all times (S4.2: Anti-Estrogenic Substances)
• Prescription: Required (Rx-only)

Evidence Quality

• Testosterone Increase: HIGH - Meta-analysis shows 273.76 ng/dL increase vs placebo (2024)
• Fertility Preservation: HIGH - Maintains spermatogenesis unlike TRT
• Long-Term Safety: MODERATE - 74% symptom improvement after 8 years
• Comparative to TRT: HIGH - Non-inferior for testosterone, preserves fertility

Key Advantage Over TRT

Unlike exogenous testosterone, clomiphene does not suppress endogenous gonadotropin secretion, preserving spermatogenesis and testicular size while increasing testosterone levels.

2. Chemical Structure & Pharmacology

Molecular Composition

Chemical Formula: C26H28ClNO·C6H8O7 (clomiphene citrate salt) Molecular Weight: 598.1 g/mol CAS Number: 50-41-9 IUPAC Name: 2-[2-chloro-1,2-diphenylethenyl)-phenoxy]-N,N-diethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate

Chemical Class: Triphenyl ethylene stilbene derivative

Stereoisomeric Composition

Non-Racemic Mixture:

• Enclomiphene (trans-isomer): ~62%
• Zuclomiphene (cis-isomer): ~38%

Each isomer has unique pharmacologic properties with distinct biological effects.

Isomer-Specific Pharmacology

Enclomiphene (Trans-Isomer):

• More potent anti-estrogenic activity
• Pro-androgenic: Promotes testosterone production
• Half-life: ~10 hours
• Primary driver of LH/FSH stimulation

Zuclomiphene (Cis-Isomer):

• Weak estrogenic agonist activity
• Pro-estrogenic properties
• Half-life: Several days to one week
• Accumulates in tissues; longer duration of action

Clinical Implication: The presence of zuclomiphene with its estrogenic activity may contribute to elevated estradiol levels observed in some patients on clomiphene therapy, whereas pure enclomiphene may cause slight estradiol decreases.

Structural Analogues

Enclomiphene (Androxal):

• Pure trans-isomer formulation
• Under investigation for male hypogonadism
• Lower estradiol elevation vs clomiphene

Tamoxifen:

• Related SERM
• Similar triphenylethylene structure
• Different side effect profile

Toremifene:

• Chlorinated derivative of tamoxifen
• SERM with similar mechanism

3. Mechanism of Action (Tissue-Specific)

Selective Estrogen Receptor Modulation

Hypothalamic-Pituitary Level:

• Occupies estrogen receptors in hypothalamus and pituitary
• Blocks negative feedback of estradiol on GnRH secretion
• Hypothalamus interprets low estrogen signal
• Increases pulsatile GnRH release

Pituitary Gland Response:

• GnRH stimulates LH and FSH secretion
• LH and FSH levels increase 123-177% from baseline
• Gonadotropins act on testes (males) or ovaries (females)

Testicular Effects (Males)

Leydig Cell Stimulation:

• LH binds to LH receptors on Leydig cells
• Stimulates testosterone synthesis and secretion
• Testosterone increases 99-146% from baseline
• Mean increase: 273.76 ng/dL vs placebo

Sertoli Cell Support:

• FSH binds to FSH receptors on Sertoli cells
• Supports spermatogenesis
• Maintains blood-testis barrier
• Preserves testicular size unlike TRT

Dual Agonist/Antagonist Properties

ERα (Estrogen Receptor Alpha):

• Concentration-dependent agonist/antagonist
• Antagonist with high estrogen levels
• Agonist with low estrogen levels
• Tissue-specific effects

ERβ (Estrogen Receptor Beta):

• Pure antagonist regardless of estrogen concentration
• Estrogen-blocking activity maintained

Tissue-Specific Effects

Bone:

• Estrogenic agonist activity (preserves bone density)
• Beneficial for long-term bone health

Lipid Profile:

• Mixed agonist/antagonist effects
• Generally neutral or beneficial lipid changes

Prostate:

• No direct androgenic stimulation of prostate
• Testosterone increase may affect prostate via conversion

Goal Archetype Integration

Primary Goal Alignment

Primary Use Case: Testosterone Restoration with Fertility Preservation (SERM)

Clomiphene citrate is a Selective Estrogen Receptor Modulator (SERM) that blocks estrogen negative feedback at the hypothalamus and pituitary, resulting in:

• Increased GnRH pulsatility
• Elevated LH and FSH secretion
• Stimulated endogenous testosterone production
• Preserved spermatogenesis and testicular function

When This Compound Makes Sense

• Men desiring fertility preservation - maintains sperm production unlike TRT
• Younger hypogonadal men (under 55-60) - better response rates in younger populations
• Men with functional/secondary hypogonadism - intact hypothalamus/pituitary function required
• Men with low-normal LH - indicates hypothalamic dysfunction amenable to clomiphene
• Those avoiding injectable therapies - oral administration preferred
• Post-cycle therapy (PCT) - restoration of HPTA after anabolic steroid use
• Men concerned about testicular atrophy - preserves testicular size

When to Choose Something Else

• Primary hypogonadism (testicular failure) - elevated LH indicates testes cannot respond; choose TRT
• Men over 65 with multiple comorbidities - response rates significantly lower
• History of visual disturbances - clomiphene has unique ocular side effect profile
• Liver disease or dysfunction - absolute contraindication
• Immediate maximal testosterone needed - TRT provides more predictable, higher levels
• Men sensitive to estradiol elevation - zuclomiphene isomer raises E2; consider enclomiphene instead
• Athletes subject to WADA testing - prohibited at all times (S4 category)

4. Pharmacokinetics & Formulation Comparison

Absorption

Oral Bioavailability:

• Readily absorbed orally in humans
• Enhanced by hepatic metabolism and fecal excretion pathway
• Food does not significantly affect absorption

Distribution

Tissue Distribution:

• Wide distribution to tissues
• High binding to plasma proteins
• Accumulation in fatty tissues

Metabolism

Hepatic Metabolism:

• Primary metabolism occurs in liver
• Undergoes enterohepatic recirculation
• Exact metabolic pathways not fully established
• Stereo-specific enterohepatic recycling of zuclomiphene

Excretion

Primary Route - Fecal:

• 42% excreted in feces
• 8% excreted in urine
• Excretion can occur up to 6 weeks after discontinuation

Half-Life

Composite Half-Life:

• Overall elimination half-life: ~5 days
• Increased by enterohepatic cycle and fatty tissue accumulation

Isomer-Specific:

• Zuclomiphene: Longer half-life (weeks)
• Enclomiphene: ~10 hours
• Zuclomiphene detectable for >1 month after discontinuation

Formulation Options

Brand Names:

• Clomid (discontinued brand in some markets)
• Serophene (discontinued in U.S.)

Generic Clomiphene Citrate:

• FDA-approved generic versions available
• Manufacturers: Sandoz, Teva Pharmaceuticals
• 25 mg and 50 mg tablets

Compounded Clomiphene:

• Available from compounding pharmacies
• Custom dosing (e.g., 12.5 mg for men)
• Significantly more affordable than brand ($2.21-2.60 per pill)

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

FDA-Approved Dosing (Female Ovulation Induction)

Initial Course:

• 50 mg orally once daily for 5 days
• Start on or about day 5 of menstrual cycle
• May increase to 100 mg if no ovulation after first course

Not applicable for male use - included for completeness only

Off-Label Dosing for Male Hypogonadism

Standard Dosing Protocols:

25 mg Daily or Every Other Day:

• Typical starting dose for men
• 25 mg daily for 25 days, off for 5 days (cyclical)
• Alternative: 25 mg every other day (continuous)

50 mg Daily or Every Other Day:

• Standard dose for most men
• 50 mg every other day common
• Can increase to 50 mg daily if needed

Titration Strategy:

• Start 25 mg every other day
• Follow-up labs at 1, 3, and 6 months
• Adjust dose based on efficacy every 6 months
• Titrate to 50 mg every other day or 50 mg daily if necessary

Fertility Preservation Protocol

Concurrent with TRT or As Alternative:

• 25-50 mg daily or every other day
• Maintains spermatogenesis
• Target: Testosterone 500-1,000 ng/dL
• Estradiol <60 pg/mL, T/E ratio ≥10:1

High-Dose Alternate-Day Therapy (Historical)

High-Dose Protocol (1983 Study):

• 100-400 mg on alternate days
• Used for idiopathic hypofertility
• Higher side effect profile
• Not commonly used today

Clinical Outcomes

Testosterone Increase:

• Mean increase: 273.76 ng/dL vs placebo
• 99-146% increase from baseline
• 89% of patients achieve biochemical increase

Gonadotropin Increase:

• LH: +177% from baseline
• FSH: +170% from baseline
• Estradiol: +81% (due to zuclomiphene)

Sperm Parameters:

• Sperm concentration: 15.2 → 62.8 million/mL
• Motility and morphology improvements reported

Dosing Adjustments

Age Considerations:

• Elderly: Start with 25 mg every other day
• Monitor for visual side effects

Baseline Testosterone:

• Higher doses may be needed for very low baseline testosterone
• Target normalization (300-1,000 ng/dL)

Response Monitoring:

• Check labs at 4-6 weeks
• Adjust dose if testosterone <500 ng/dL or >1,000 ng/dL
• Monitor estradiol (goal <60 pg/mL)

Age-Stratified Dosing

Dosing by Age Bracket

Age-Specific Response Factors

Why Younger Men Respond Better:

• Younger patients respond 2.3 times as likely to clomiphene treatment as patients 56 years and older
• Fewer comorbidities (diabetes, hypertension, CAD) that impair response
• More intact hypothalamic-pituitary function
• Low baseline LH predicts better response - more common in younger men

Age 65+ Special Considerations:

• Studies show significantly decreased responses with aging (P<0.05)
• Higher prevalence of comorbidities reduces efficacy
• Multiple medication use may impair response
• Consider testosterone supplementation if inadequate response to 50 mg EOD
• Monitor closely for visual disturbances (increased risk with age)

Sex-Specific Considerations

Males (Off-Label Use):

• All doses in this document refer to male off-label use
• Standard male dosing: 25-50 mg daily or every other day
• FDA approved only for female ovulation induction
• AUA guidelines support use for fertility preservation

Females:

• FDA-approved dosing: 50 mg daily for 5 days
• Starting day 5 of menstrual cycle
• May increase to 100 mg if no ovulation
• Not covered in this male-focused document

Visual Side Effect Monitoring by Age

Visual Symptoms Requiring Immediate Cessation:

• Blurring, spots, flashes (scintillating scotomata)
• Palinopsia (prolonged afterimages)
• Photophobia or diplopia
• Any decrease in visual acuity

6. Pivotal Clinical Trials & Evidence

Meta-Analyses & Systematic Reviews (2024)

2024 Systematic Review: SERMs vs Placebo, TRT, and HCG

Study Design: Systematic search of PubMed, Embase, Cochrane Library, ClinicalTrials.gov through July 2024; 10 RCTs included

Key Findings:

• Testosterone increase: MD 273.76 ng/dL (95% CI: 191.87-355.66; p<0.01) vs placebo
• LH increase: MD 4.66 IU/L (95% CI: 3.37-5.94; p<0.01)
• FSH increase: MD 4.59 IU/L (95% CI: 2.88-6.30; p<0.01)
• SERMs vs HCG: Testosterone higher with SERMs (158 vs 134 ng/dL; p<0.002)
• SERMs vs Testosterone Gel: Non-significant difference in testosterone levels
• Safety: No substantial adverse events

Conclusion: SERMs effectively increase testosterone in functional hypogonadism and should be considered alternative to testosterone gel

2024-2025 Meta-Analysis: Clomiphene for Pregnancy Rates

Study Design: Systematic review on clomiphene efficacy for pregnancy in idiopathic male subfertility

Results:

• Clomiphene and placebo had similar pregnancy rates (10.4% vs 7.1%; OR 1.30; p=0.74)
• Limited evidence for pregnancy improvement
• Hormonal benefits clearer than fertility outcomes

2022 Meta-Analysis: Clomiphene for Male Hypogonadism

Study Design: Systematic review and meta-analysis

Findings:

• Total testosterone: 9 → 16 nmol/L
• 89% of patients achieved biochemical testosterone increase
• Significant increases in FSH, LH, testosterone, estradiol

Randomized Controlled Trials

2024 RCT: Clomiphene for Idiopathic Oligoasthenozoospermia

Study Design: 50 infertile men randomized to clomiphene 50mg daily × 3 months or placebo

Results:

• Significant improvements in FSH, LH, testosterone levels
• Sperm concentration improvements
• ADAM score (hypogonadal symptom) improvements

2023 Case Report: Long-Term Dose-Dependent Response

Study Design: First report of sustained clomiphene response for 7 years

Findings:

• Dose-dependent testosterone response sustained for 7 years
• 74% of patients maintained symptom improvement after 8 years
• Demonstrates long-term safety and efficacy

2014 Long-Term Safety Study

Study Design: Patients treated >3 years with clomiphene

Adverse Events (Long-Term >3 Years):

• Mood changes: 5 patients
• Blurred vision: 3 patients
• Breast tenderness: 2 patients
• Overall well-tolerated

2023 Comparative Study: Enclomiphene vs Clomiphene

Study Design: 66 patients, retrospective comparison

Results:

• Enclomiphene: Median testosterone increase 166 ng/dL
• Clomiphene: Median testosterone increase 98 ng/dL (p=0.20, non-significant)
• Enclomiphene: Lower estradiol change (–5.92 pg/mL)
• Enclomiphene: Lower adverse event rate (decreased libido, energy, mood)

Observational Studies

2024 Study: Hormonal Changes on Clomiphene

Study Results:

• Testosterone: +99.2% at 4-6 weeks
• Estradiol: +80.8%
• LH: +123.1%
• FSH: +101.3%

Evidence Quality Assessment

Testosterone Increase:

• Level of Evidence: 1a (Systematic reviews and meta-analyses of RCTs)
• Recommendation Grade: A (Strong)

Fertility Preservation:

• Level of Evidence: 2a (Systematic reviews of cohort studies)
• Recommendation Grade: B (Moderate-Strong)

Long-Term Safety:

• Level of Evidence: 2b (Individual cohort studies)
• Recommendation Grade: B (Moderate)

Pregnancy Outcomes:

• Level of Evidence: 1a (Meta-analysis of RCTs)
• Recommendation Grade: C (Weak - no clear benefit for pregnancy rates)

7. Safety Profile + Black Box Warnings

FDA Black Box Warnings

No Black Box Warning for Clomiphene

Clomiphene does not carry FDA black box warnings. However, important safety warnings exist.

Visual Disturbances (Unique to Clomiphene)

Incidence and Characteristics:

• Blurring, spots, flashes (scintillating scotomata) may occur
• Incidence increases with dose and duration
• Usually reversible upon discontinuation
• Cases of prolonged/irreversible visual disturbances reported

Serious Visual Disorders (Rare):

• Ischemic optic neuropathy
• Central retinal vein occlusion
• Retinal detachment
• Risk of serious visual disturbances potentially leading to blindness

Management:

• Patients with visual symptoms should discontinue treatment
• Complete ophthalmological evaluation required
• Warn patients about driving/machinery hazards with visual changes

Common Adverse Effects

Mood and Psychiatric:

• Mood swings, irritability, anxiety
• Sleep disturbances
• Headaches
• Depression, emotionality

Hormonal:

• Gynecomastia
• Hot flashes
• Breast tenderness (2/N in long-term study)

Gastrointestinal:

• Nausea
• Abdominal discomfort

Other:

• Dizziness, vertigo
• Fatigue

Serious Adverse Events (Rare)

Liver Toxicity:

• Low rate of transient serum aminotransferase elevations
• Rare instances of clinically apparent liver injury
• Can be severe and even fatal
• Contraindicated in liver disease or dysfunction history

Ovarian Hyperstimulation Syndrome (OHSS) - Female Only:

• Rapid progression to serious medical disorder possible
• Not applicable in male patients

Hypertriglyceridemia:

• Cases reported, especially with family history of hyperlipidemia
• Higher dose/longer duration increases risk

Ovarian Tumor Risk (Female) - Prolonged Use:

• Increased risk of borderline or invasive ovarian tumor
• Not applicable in male patients

Safety Comparison: Clomiphene vs TRT

Advantages of Clomiphene:

• Lower polycythemia risk than TRT
• Preserves fertility and spermatogenesis
• Maintains testicular size
• No suppression of endogenous hormones

Disadvantages vs TRT:

• Visual disturbance risk (unique to clomiphene)
• Mood changes potentially more common
• Elevated estradiol due to zuclomiphene
• Daily oral medication vs weekly/biweekly injections

Overall Safety Conclusion: Clomiphene is generally considered safe, with the majority of studies not reporting significant side effects. Long-term use (>3 years) appears well-tolerated.

8. Formulation Options & Administration

Available Formulations

Generic Clomiphene Citrate (Widely Available):

• 25 mg oral tablets
• 50 mg oral tablets
• Manufacturers: Sandoz, Teva Pharmaceuticals

Brand Names (Mostly Discontinued):

• Clomid: Discontinued brand in some markets
• Serophene: Discontinued in U.S.

Compounded Formulations:

• Available from compounding pharmacies
• Custom dosing (e.g., 12.5 mg, 25 mg for men)
• More affordable: $2.21-2.60 per pill

Administration

Oral Administration:

• Taken by mouth with or without food
• Swallow whole; do not crush or chew
• Consistent timing preferred but not required

Dosing Schedule:

• Daily (25 mg or 50 mg)
• Every other day (25 mg or 50 mg)
• Cyclical (25 days on, 5 days off)

Timing Considerations

Time of Day:

• No specific time-of-day requirement
• Consistent timing may help adherence
• Can be taken morning or evening

Food Interactions:

• No significant food interactions
• Take with food if GI upset occurs

Missed Dose:

• Take as soon as remembered if same day
• Skip if close to next scheduled dose
• Do not double dose

9. Storage & Stability

Storage Conditions

Temperature:

• Store between 15-30°C (59-86°F)
• Room temperature storage stable
• No refrigeration required

Protection Requirements:

• Protect from heat, light, and moisture
• Store in closed containers
• Do not store in bathroom (high humidity)

Packaging:

• Blister packs increase protection from humidity and light
• Blister packaging prolongs storage lifespan

Shelf Life

Expiration:

• Properly stored medications typically last 2-3 years
• Check manufacturer expiration date
• Discard after expiration date

Disposal

Proper Disposal:

• Take to medication take-back program
• Do not flush down toilet
• Follow FDA medication disposal guidelines

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA Regulatory Status

Approval History:

• Approval Date: February 1, 1967
• IND Filed: 1963 (third IND ever filed with FDA)
• Development Duration: 11-year process from synthesis to approval
• Approval Characterization: "Significant new drug approval" by 1967 FDA annual report

FDA-Approved Indication:

• Treatment of ovulatory dysfunction in women desiring pregnancy
• Initially for oligomenorrhea, expanded to anovulation

Off-Label Male Use:

• Not FDA-approved for men
• Widely used off-label for male hypogonadism and infertility
• Supported by AUA guidelines for fertility preservation

Prescription Status:

• Prescription (Rx) required
• Not available over-the-counter

DEA Federal Status

Controlled Substance Classification:

• Not a federally controlled substance
• No DEA scheduling
• Prescription-only medication

WADA Prohibited List Status

S4: Hormone and Metabolic Modulators

Classification: S4.2 - Anti-Estrogenic Substances (SERMs)

Prohibition Status:

• Prohibited at all times (in- and out-of-competition)
• Listed alongside tamoxifen and other SERMs

Rationale for Prohibition:

• Stimulates testosterone production
• Performance-enhancing potential
• Used in post-cycle therapy after anabolic steroid use

Prevalence in Testing:

• 39% of S4 adverse analytical findings in 2020 from SERMs (tamoxifen and clomiphene)
• Common detection in anti-doping tests

Therapeutic Use Exemptions (TUE):

• Athletes may apply for TUE
• Requires documented medical need
• Must apply in advance of use

International Regulatory Status

General Status Worldwide:

• Prescription medication in most countries
• Similar indications (female ovulation induction)
• Off-label male use varies by region

Australia (TGA):

• Schedule 4 (Prescription Only Medicine)

Canada (Health Canada):

• Prescription medication
• Similar off-label use patterns

European Union (EMA):

• Prescription medication
• Variable national regulations

Regulatory Summary Table

11. Product Cross-Reference (Compounding vs Brand)

Brand Name Products (Mostly Discontinued)

Clomid (Historical Brand)

Status:

• Generic FDA-approved version available
• Brand-name Clomid discontinued by some manufacturers
• May still be available in limited markets

Formulations:

• 50 mg tablets

Historical Pricing:

• $100-250 for one-month supply (30 tablets)

Serophene

Status:

• Discontinued in United States

Generic Clomiphene Citrate

Manufacturers:

• Sandoz
• Teva Pharmaceuticals

Formulations:

• 25 mg and 50 mg tablets

Pricing (2024):

• Retail (no coupon): $20-80 per month
• With GoodRx coupon: $156 for 30 × 50mg brand-name tablets
• With SingleCare coupon: $50.30 for 5 × 50mg generic tablets
• Average without insurance: $423.99 for 30 × 50mg

Compounded Clomiphene

Availability:

• Available from compounding pharmacies nationwide
• Custom dosing for male patients (e.g., 12.5 mg, 25 mg)

Pricing:

• 25 mg compounded: $2.21 ± $1.24 per pill
• 50 mg compounded: $2.60 ± $1.49 per pill
• Brand Clomid: $8.41 ± $1.53 per pill
• Compounded significantly more affordable than brand (p<0.001)

Cost Comparison Summary

Cost-Effectiveness Analysis:

For 50 mg daily (common male dose):

• Brand: $100-250/month
• Generic (with coupon): $156/month
• Generic (without coupon): $20-80/month
• Compounded: $78/month

Annual Cost Estimates:

• Brand: $1,200-3,000/year
• Generic: $240-960/year
• Compounded: $936/year

Insurance Coverage

Coverage Status:

• Despite role in male infertility/hypogonadism management, rarely covered by insurance for these indications
• More than half of Medicaid plans require prior authorization
• Medicaid generally does not cover infertility treatments

When Covered:

• Insurance plans that cover clomiphene typically place it in lowest copay tiers
• Results in low copay cost
• Female ovulation induction more likely to be covered than male use

Product Quality Considerations

Generic Bioequivalence:

• FDA-approved generics bioequivalent to brand
• Same active ingredient and dosage
• May differ in inactive excipients

Compounded Quality:

• Regulated by state pharmacy boards
• Variable quality control standards
• Significantly more affordable alternative given limited insurance coverage

12. Monitoring & Lab Values

Pre-Treatment Baseline Testing

Hormonal Panel (Essential):

1. Total Testosterone:

   • Two morning samples (7-11 AM) on separate days
   • Diagnostic threshold: <300 ng/dL for hypogonadism
   • Reference range: 200-1,000 ng/dL

2. Free Testosterone:

   • More accurate reflection of bioavailable testosterone
   • Calculated or direct measurement

3. Luteinizing Hormone (LH):

   • Baseline: Median 4.2 mIU/mL (IQR: 2.8-6.2)
   • Reference range: 2-12 mIU/mL
   • Low or low-normal LH suggests hypogonadotropic hypogonadism

4. Follicle-Stimulating Hormone (FSH):

   • Baseline: Median 4.3 mIU/mL (IQR: 2.7-7.3)
   • Reference range: 1.6-9 mIU/mL
   • Low FSH may predict better clomiphene response

5. Estradiol (Sensitive Assay):

   • Baseline measurement before starting therapy
   • Clomiphene artificially elevates estradiol through zuclomiphene

Hematologic Panel:

6. Complete Blood Count (CBC):
   • Baseline hematocrit
   • Target hematocrit <54%
   • Lower polycythemia risk than TRT

Metabolic Panel:

7. Comprehensive Metabolic Panel (CMP):
   • Liver function (AST, ALT) - critical given liver contraindication
   • Kidney function
   • Electrolytes

Optional Baseline Tests:

8. Prolactin:

   • If baseline testosterone <300 ng/dL
   • Rule out hyperprolactinemia

9. Sex Hormone Binding Globulin (SHBG):

   • Calculates free testosterone
   • Baseline reference

10. Semen Analysis (If Fertility Goal):

    • Baseline sperm concentration, motility, morphology
    • Track improvement on therapy

On-Treatment Monitoring Schedule

2-4 Weeks After Starting:

• Initial follow-up to ensure appropriate response
• Any dosage change requires repeat labs 2-4 weeks later

4-6 Week Follow-Up (Standard):

Median time to initial follow-up: 6 weeks (IQR: 4-9 weeks)

Hormones to Check:

• Total Testosterone: Goal 500-1,000 ng/dL
• Estradiol: Goal <60 pg/mL and T/E ratio ≥10:1
• LH and FSH: Confirm gonadotropin stimulation
• Hematocrit: Goal <54%

Expected Changes on Clomiphene:

• Testosterone: +99.2% increase
• Estradiol: +80.8% increase
• LH: +123.1% increase
• FSH: +101.3% increase

6-Month Follow-Up:

• Once hormonal levels normalized, repeat labs at 6 months
• Check: Testosterone, estradiol, hematocrit

Annual Monitoring (Long-Term):

• Labs every 12 months while on medication
• Full hormonal panel
• CBC with differential
• CMP (liver function)
• Semen analysis if fertility goal

Critical Monitoring Thresholds

Testosterone:

• <500 ng/dL: Consider dose increase
• 500-1,000 ng/dL: Therapeutic range
• >1,000 ng/dL: Reduce dose

Estradiol:

• <60 pg/mL: Acceptable
• >60 pg/mL and T/E ratio <10:1: Consider aromatase inhibitor or enclomiphene

Hematocrit:

• <50%: Continue therapy
• 50-54%: Monitor closely
• >54%: Dose reduction or temporary discontinuation

LH/FSH:

• Expected to increase significantly
• Clomiphene artificially elevates LH/FSH (not diagnostic of primary hypogonadism)

Laboratory Test Summary Table

Bloodwork Impact Mapping

Expected Marker Changes on Clomiphene

Understanding the Hormonal Changes

Why LH and FSH Increase Dramatically:

• Clomiphene blocks estrogen receptors in hypothalamus and pituitary
• Brain interprets blocked estrogen signal as low estrogen state
• Increased GnRH pulsatility drives gonadotropin release
• LH/FSH elevations are NOT pathologic - they are the therapeutic mechanism

Why Estradiol Increases:

• Zuclomiphene isomer (38% of clomiphene) has estrogenic activity
• Higher testosterone undergoes aromatization to estradiol
• Combined effect results in ~81% E2 elevation
• If E2 problematic, consider switching to enclomiphene (no zuclomiphene)

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by Response Markers

13. Drug Interactions & Contraindications - Comprehensive

Absolute Contraindications

Liver Disease:

• Liver disease or history of liver dysfunction
• Mechanism: Clomiphene undergoes enterohepatic circulation and is metabolized by liver
• Risk: Low rate of transient aminotransferase elevations; rare severe/fatal liver injury

Hypersensitivity:

• Known allergy to clomiphene citrate or any ingredient

Female-Specific (Not Applicable to Males):

• Pregnancy
• Abnormal uterine bleeding of undetermined origin

Other Contraindications:

• Uncontrolled adrenal dysfunction

Visual Concerns - Critical Safety Information

Types of Visual Disturbances:

• Blurred vision, spots, flashes (scintillating scotomata)
• Palinopsia (prolonged afterimages) - may persist 2-7 years
• Photophobia and diplopia
• Central and peripheral scotomas

Serious Ocular Complications (Rare):

• Ischemic optic neuropathy (NAION)
• Central retinal vein occlusion
• Retinal detachment and vitreous detachment
• Maculopathy with extended use
• Risk of partial or complete blindness in rare cases

Risk Factors:

• Higher dose and longer duration increase risk
• Older age (65+)
• Pre-existing disc-at-risk (small optic cup-to-disc ratio)
• History of optic nerve disorders

Management Protocol:

1. Baseline: Consider ophthalmologic exam before starting (especially age 65+)
2. During therapy: Warn patients about symptoms; advise caution with driving/machinery
3. If symptoms occur: Discontinue immediately and obtain complete ophthalmologic evaluation
4. Do not resume if visual symptoms occurred

Prescription Medication Interactions

Tamoxifen vs Clomiphene: Head-to-Head Comparison

Combined SERM Use (PCT Context):

• Stacked PCT using both clomiphene and tamoxifen may be used for multi-compound recovery
• Clomiphene provides high LH/FSH spike
• Tamoxifen improves estrogen management and softens clomiphene mood effects
• Monitor total SERM exposure and side effects

Other Compounds (Stacking Interactions)

Supplements

Foods/Timing

Relative Contraindications & Warnings

Hypertriglyceridemia:

• Risk Factors: Preexisting or family history of hyperlipidemia
• Higher dose/longer duration increases risk

Prolonged Use:

• Increased risk of borderline or invasive ovarian tumor (female specific)

Special Populations

Male Use (Off-Label):

• Not FDA-approved for males
• AUA guidelines support use for fertility preservation
• Requires careful discussion and experienced andrologist

Geriatric:

• Limited data in elderly men
• Start with lower doses (25 mg)
• Monitor for visual side effects

Hepatic Impairment:

• Contraindicated (see above)

Renal Impairment:

• Limited data; use with caution
• Monitor renal function

Warnings & Precautions Summary

Black Box Warnings: None

Serious Warnings:

1. Visual disturbances (potentially irreversible)
2. Liver toxicity (rare but potentially severe/fatal)
3. Hypertriglyceridemia (especially with family history)

Common Precautions:

• Monitor visual changes (stop if occurs)
• Baseline and periodic liver function tests
• Monitor estradiol and testosterone
• Ophthalmologic examination if visual symptoms

14. References & Citations

Meta-Analyses & Systematic Reviews

1. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: systematic review and meta-analysis (2024)
2. Efficacy of clomiphene citrate and tamoxifen on pregnancy rates in idiopathic male subfertility: systematic review and meta-analysis (2024-2025)
3. Clomiphene citrate for men with hypogonadism: systematic review and meta-analysis (2022)

Clomiphene Mechanism & Pharmacology

4. Clomiphene - StatPearls (2024)
5. Clomifene: Uses, Interactions, Mechanism of Action - DrugBank
6. Clomiphene citrate elicits estrogen agonistic/antagonistic effects differentially via ERα and ERβ (2010)
7. Clomifene - Wikipedia

Clinical Trials & Efficacy Studies

8. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism (2024)
9. Dose-dependent response to long-term clomiphene citrate in male functional hypogonadotropic hypogonadism (2023)
10. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (2024)
11. Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment (2023)
12. Clomiphene citrate improves sperm parameters in infertile men with idiopathic oligoasthenozoospermia (2024)
13. Temporal Changes of Clomiphene on Testosterone Levels and Semen Parameters (2023)

Comparative Studies

14. Clomiphene and enclomiphene show comparable efficacy to testosterone in functional hypogonadism (2024)

Pharmacokinetics

15. Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents - PMC (2017)
16. Pharmacokinetics of intravenous clomiphene isomers - PMC

Dosing Protocols

17. Clomiphene / Clomid for Male Infertility - Male Infertility Guide
18. Clomid for Male Infertility - Austin Fertility Docs
19. How Clomiphene Helps Men with Low Testosterone - Huddle Men's Health
20. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency (2012)
21. Clomid for Men: Uses & How it Works - Hims

Safety & Side Effects

22. Clomid (Clomiphene): Side Effects, Uses, Dosage, Interactions, Warnings - RxList
23. Clomiphene Citrate for Male Hypogonadism and Infertility: An Updated Review (2020)
24. Visual disturbance secondary to clomiphene citrate - PubMed (1995)
25. Clomiphene: Risk of Serious Visual Disturbances Potentially Leading to Blindness - NPRA Malaysia (2023)
26. Long-Term Safety and Efficacy of Clomiphene Citrate for Hypogonadism - Journal of Urology (2014)
27. Clomid, Serophene (clomiphene) dosing, indications, interactions - Medscape
28. Clomiphene: Uses, Side Effects, Interactions - WebMD

Liver Safety

29. Clomiphene - LiverTox - NCBI Bookshelf

Regulatory & Cost

30. Generic Clomid Availability - Drugs.com
31. Clomiphene and enclomiphene: Drugs, not dietary supplements - OPSS
32. The Cost of Clomiphene for Male Infertility Treatment: Regional Price Variability (2024)
33. Cost of Male Fertility Medications - Male Infertility Guide
34. How Much Is Clomid Without Insurance? - GoodRx
35. Clomid Coupons 2025 - SingleCare
36. Clomiphene 2025 Prices - GoodRx
37. How Much Does Clomid Cost Without Insurance? - Alpha MD

FDA Approval History

38. Clomiphene citrate at 50: the dawning of assisted reproduction - Fertility and Sterility (2017)
39. Clomiphene Citrate - Embryo Project Encyclopedia

AUA Guidelines & Off-Label Use

40. Testosterone Deficiency Guideline - American Urological Association
41. Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018)
42. USANZ - Clomiphene Use for Male Infertility, Oligospermia and Hypogonadism
43. Clomiphene citrate therapy for testosterone deficiency: proposed clinical care pathway (2023)

Monitoring & Lab Values

44. Ceiling effect of clomiphene citrate on testosterone to estradiol ratio (2022)
45. Baseline gonadotropin levels and testosterone response in hypogonadal men treated with clomiphene (2020)
46. Hormone Testing and Interpretation for Male Infertility - Male Infertility Guide
47. HRT Lab Testing Schedule for Clomiphene - Hone Health

WADA Prohibited List

48. Substance Profile: Clomiphene - USADA
49. The World Anti-Doping Code in sport: Update for 2015 - PMC
50. The Prohibited List - World Anti Doping Agency
51. Drugs Banned in Sport - Drugs.com
52. Illegal and falsified medicines self-administrated in post-cycle therapy - PMC (2024)

Stereoisomers (Zuclomiphene vs Enclomiphene)

53. What's the Difference between Clomiphene/Clomid vs. Enclomiphene - Houman MD
54. Zuclomifene - ScienceDirect Topics
55. Enclomifene - ScienceDirect Topics
56. The Isomers of Clomiphene Citrate have Dissimilar Dispositions Once Ingested (ADME study)
57. Fertility-Friendly Hormone Therapy: Enclomiphene, Clomiphene, and Anastrozole - Men's Reproductive Health

Storage & Handling

58. Clomiphene Citrate Storage Instructions - Hone Health
59. Refrigeration vs. Room Temperature: Storing PCOS Drugs - Oana Health
60. Clomiphene: Uses & Side Effects - Cleveland Clinic

Additional Clinical Resources

61. Clomiphene citrate: A potential alternative for testosterone therapy in hypogonadal males (2023)
62. Clomiphene: Uses, Dosage, Side Effects - Drugs.com
63. Male Hypogonadotropic Hypogonadism: The Emerging Role of Clomiphene - Cleveland Clinic Consult QD

Document Prepared By: Research Team, Epiq Aminos Total References: 63 Word Count: ~16,500 Date: December 2024